Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Don't forget QOF in payment by results health systems.
As well as the three main reasons for treating diabetes listed in the article, there is, in England, a driving force that may cloud judgment and clinical common sense, ie QOF. Practice income needed to pay staff and run services depends on hitting targets including HBAic results. This may automatically lead to extra treatment with newer agents, potentially harming people. Those that set QOF targets in diabetes and many other areas seem not to recognise that even in clinical trials most people do not get to or keep at target levels.
Re: Helping patients make sense of the risks of taking GLP-1 agonists
Don't forget QOF in payment by results health systems.
As well as the three main reasons for treating diabetes listed in the article, there is, in England, a driving force that may cloud judgment and clinical common sense, ie QOF. Practice income needed to pay staff and run services depends on hitting targets including HBAic results. This may automatically lead to extra treatment with newer agents, potentially harming people. Those that set QOF targets in diabetes and many other areas seem not to recognise that even in clinical trials most people do not get to or keep at target levels.
Competing interests: No competing interests